Publication: Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in bangkok, Thailand
Issued Date
2009-08-01
Resource Type
ISSN
15254135
Other identifier(s)
2-s2.0-68449096170
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Acquired Immune Deficiency Syndromes. Vol.51, No.5 (2009), 601-608
Suggested Citation
Wanitchaya Kittikraisak, Frits Van Griensven, Michael Martin, Janet McNicholl, Peter B. Gilbert, Rutt Chuachoowong, Suphak Vanichseni, Ruengpung Sutthent, Jordan W. Tappero, Timothy D. Mastro, Dale J. Hu, Marc Gurwith, Dwip Kitayaporn, Udomsak Sangkum, Kachit Choopanya Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in bangkok, Thailand. Journal of Acquired Immune Deficiency Syndromes. Vol.51, No.5 (2009), 601-608. doi:10.1097/QAI.0b013e3181a44700 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27998
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in bangkok, Thailand
Other Contributor(s)
Thailand Ministry of Public Health
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
University of Washington, Seattle
Mahidol University
Bangkok Vaccine Evaluation Group
VaxGen, Inc.
Bangkok Metropolitan Administration
Bumrungrad International Hospital
Family Health International
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
University of Washington, Seattle
Mahidol University
Bangkok Vaccine Evaluation Group
VaxGen, Inc.
Bangkok Metropolitan Administration
Bumrungrad International Hospital
Family Health International
Abstract
BACKGROUND:: We investigated effects of vaccination with AIDSVAX B/E HIV-1 candidate vaccine on blood and seminal plasma HIV-1 RNA viral loads (BVL and SVL, respectively) in vaccine recipients (VRs) and placebo recipients (PRs) who acquired infection. METHODS:: Linear mixed models were fitted for repeated measurements of BVL. Generalized estimating equations were used to assess the difference in SVL detectability between VRs and PRs. RESULTS:: A total of 196 participants became HIV-1 infected during the trial. Thirty-two (16%) became infected with HIV-1 subtype B and 164 (84%) with HIV-1 subtype CRF01-AE. Per protocol-specified analysis, there were no differences in BVL levels between VRs and PRs. When stratified by HIV-1-infecting subtype, vaccination with AIDSVAX B/E was initially associated with higher BVL among HIV-1 CRF01-AE-infected VRs compared with HIV-1 CRF01-AE-infected PRs; however, this difference did not persist over time. HIV-1 subtype B-infected VRs had slightly higher BVL levels and were more likely to have detectable SVL during the follow-up period than HIV-1 subtype B-infected PRs. CONCLUSIONS:: Subtle differences in BVL and SVL were detected between VRs and PRs. These results may help to further understand the dynamics between HIV-1 vaccination, HIV-1-infecting subtypes, and subsequent viral expression in different body compartments. Copyright © 2009 by Lippincott Williams & Wilkins.